Riboflavin analogs as antiinfectives: Occurrence, mode of action, metabolism and resistance

Current Pharmaceutical Design

Volumn 19, Issue 14, 2013, Pages 2552-2560

  Pedrolli, Danielle Biscaro ^a   Jankowitsch, Frank ^a   Schwarz, Julia ^a   Langer, Simone ^a   Nakanishi, Shinobu ^a   Frei, Eva ^b   Mack, Matthias ^a  

^a MANNHEIM UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

8 demethyl 8 amino riboflavin; Antimetabolites; Flavoenzymes; FMN riboswitches; Riboflavin (vitamin B2) analogs; Roseoflavin; Streptomyces davawensis

Indexed keywords

ANTIINFECTIVE AGENT; FLAVINE ADENINE NUCLEOTIDE; FLAVOPROTEIN; MOLYBDOPTERIN; RIBOFLAVIN DERIVATIVE; ROSEOFLAVIN; UNCLASSIFIED DRUG;

ANTIBIOTIC BIOSYNTHESIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS CEREUS; BACILLUS SUBTILIS; CYTOLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LISTERIA MONOCYTOGENES; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; RIBOSWITCH; STAPHYLOCOCCUS AUREUS; STREPTOMYCES; STREPTOMYCES COELICOLOR; STREPTOMYCES DAVAWENSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; MOLECULAR STRUCTURE; RIBOFLAVIN;

EID: 84877822573     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319140006     Document Type: Article

References (62)

1. Bardos TJ. Antimetabolites: molecular design and mode of action. Top Curr Chem 1974; 52: 63-98.
2. Mack M, Grill S. Riboflavin analogs and inhibitors of riboflavin biosynthesis. Appl Microbiol Biotechnol 2006; 71: 265-75.
3. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997; 24: S18-30-S18-39.
4. Murthy YV, Massey V. Syntheses and applications of flavin analogs as active site probes for flavoproteins. Methods Enzymol 1997; 280: 436-60.
5. Abbas CA, Sibirny AA. Genetic control of biosynthesis and transport of riboflavin and flavin nucleotides and construction of robust biotechnological producers. Microbiol Mol Biol Rev 2011; 75: 321-60.
6. Fischer M, Bacher A. Biosynthesis of flavocoenzymes. Nat Prod Rep 2005; 22: 324-50.
7. Ghisla S, Massey V. New flavins for old: artificial flavins as active site probes of flavoproteins. Biochem J 1986; 239: 1-12.
8. Macheroux P, Kappes B, Ealick SE. Flavogenomics-a genomic and structural view of flavin-dependent proteins. Febs J 2011; 278: 2625-34.
9. Grininger M, Staudt H, Johansson P, Wachtveitl J, Oesterhelt D. Dodecin is the key player in flavin homeostasis of archaea. J Biol Chem 2009; 284: 13068-76.
10. Monaco HL. Crystal structure of chicken riboflavin-binding protein. Embo J 1997; 16: 1475-83.
11. Singer TP, Edmondson DE. 8 alpha-substituted flavins of biological importance. FEBS Lett 1974; 42: 1-14.
12. Ghisla S, Mayhew SG. Identification and properties of 8-hydroxyflavin--adenine dinucleotide in electron-transferring flavoprotein from Peptostreptococcus elsdenii. Eur J Biochem 1976; 63: 373-90.
13. Bashiri G, Rehan AM, Greenwood DR, Dickson JM, Baker EN. Metabolic engineering of cofactor F420 production in Mycobacterium smegmatis. PLoS One 2010; 5: e15803.
14. DiMarco AA, Bobik TA, Wolfe RS. Unusual coenzymes of methanogenesis. Annu Rev Biochem 1990; 59: 355-94.
15. Purwantini E, Gillis TP, Daniels L. Presence of F420-dependent glucose-6-phosphate dehydrogenase in Mycobacterium and Nocardia species, but absence from Streptomyces and Corynebacterium species and methanogenic Archaea. FEMS Microbiol Lett 1997; 146: 129-34.
16. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
17. Leimkuhler S, Wuebbens MM, Rajagopalan KV. The History of the Discovery of the Molybdenum Cofactor and Novel Aspects of its Biosynthesis in Bacteria. Coord Chem Rev 2011; 255: 1129-44.
18. Mendel RR, Kruse T. Cell biology of molybdenum in plants and humans. Biochim Biophys Acta 2012.
19. Otani S, Kasai S, Matsui K. Isolation, chemical synthesis and properties of roseoflavin. Methods in enzymology: Academic Press, 1980. p. 235-41.
20. Otani S, Takatsu M, Nakano M, Kasai S, Miura R. Letter: Roseoflavin, a new antimicrobial pigment from Streptomyces. J Antibiot (Tokyo) 1974; 27: 88-9.
21. Jankowitsch F, Kuhm C, Kellner R, et al. A novel N, N-8-amino-8-demethyl-D-riboflavin Dimethyltransferase (RosA) catalyzing the two terminal steps of roseoflavin biosynthesis in Streptomyces davawensis. J Biol Chem 2011; 286: 38275-85.
22. Juri N, Kubo Y, Kasai S, Otani S, Kusunose M, Matsui K. Formation of roseoflavin from 8-amino-and 8-methylamino-8-demethyl-D-riboflavin. J Biochem (Tokyo) 1987; 101: 705-11.
23. Grill S, Yamaguchi H, Wagner H, Zwahlen L, Kusch U, Mack M. Identification and characterization of two Streptomyces davawensis riboflavin biosynthesis gene clusters. Arch Microbiol 2007; 188: 377-87.
24. Wallace WC, Holmlund CE. Effect of riboflavon analogs on the growth of Tetrahymena pyriformis. J Nutr 1980; 110: 2113-6.
25. Kashchenko VE, Shavlovskii GM, Babiak L. [Effect of riboflavin analogs on Pichia guilliermondii growth]. Mikrobiologiia 1982; 51: 593-600.
26. Kasai S, Yamanaka S, Wang SC, Matsui K. Anti-riboflavin activity of 8-O-alkyl derivatives of riboflavin in some Gram-positive bacteria. J Nutr Sci Vitaminol (Tokyo) 1979; 25: 289-98.
27. Kasai S, Kubo Y, Yamanaka S, et al. Anti-riboflavin activity of 8N-alkyl analogues of roseoflavin in some Gram-positive bacteria. J Nutr Sci Vitaminol (Tokyo) 1978; 24: 339-50.
28. Halladay PK, Hunt NH, Butcher GA, Cowden WB. Antimalarial action of flavin analogues seems not be due to inhibition of glutathione reductase of host erythrocytes. Biochem Pharmacol 1990; 39: 1063-5.
29. Kearney EB, Singer TP. The L-amino acid oxidases of snake venom. III. Reversible inactivation of L-amino acid oxidases. Arch Biochem Biophys 1951; 33: 377-96.
30. Hasford J, Rizzo C. Linear free energy substituent effect on flavin redox chemistry. Journal of the American Chemical Society 1998; 120: 2251-5.
31. Winkler WC, Breaker RR. Regulation of bacterial gene expression by riboswitches. Annu Rev Microbiol 2005; 59: 487-517.
32. Mironov AS, Gusarov I, Rafikov R, et al. Sensing small molecules by nascent RNA: a mechanism to control transcription in bacteria. Cell 2002; 111: 747-56.
33. Winkler WC, Cohen-Chalamish S, Breaker RR. An mRNA structure that controls gene expression by binding FMN. Proc Natl Acad Sci USA 2002; 99: 15908-13.
34. Lee ER, Blount KF, Breaker RR. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol 2009; 6: 187-94.
35. Ott E, Stolz J, Lehmann M, Mack M. The RFN riboswitch of Bacillus subtilis is a target for the antibiotic roseoflavin produced by Streptomyces davawensis. RNA Biol 2009; 6: 276-80.
36. Pedrolli DB, Matern A, Wang J, et al. A highly specialized FMN riboswitch responds differently to similar ligands and confers roseoflavin resistance to Streptomyces davawensis. Nucleic Acids Res 2012; 40(17): 8662-73.
37. Mansjo M, Johansson J. The riboflavin analog roseoflavin targets an FMN-riboswitch and blocks Listeria monocytogenes growth, but also stimulates virulence gene-expression and infection. RNA Biol 2011; 8: 674-80.
38. Matsui K, Juri N, Kubo Y, Kasai S. Formation of roseoflavin from guanine through riboflavin. J Biochem (Tokyo) 1979; 86: 167-75.
39. Vogl C, Grill S, Schilling O, Stulke J, Mack M, Stolz J. Characterization of riboflavin (vitamin B2) transport proteins from Bacillus subtilis and Corynebacterium glutamicum. J Bacteriol 2007; 189: 7367-75.
40. Hemberger S, Pedrolli DB, Stolz J, Vogl C, Lehmann M, Mack M. RibM from Streptomyces davawensis is a riboflavin/roseoflavin transporter and may be useful for the optimization of riboflavin production strains. BMC Biotechnol 2011; 11: 119.
41. Grill S, Busenbender S, Pfeiffer M, Kohler U, Mack M. The bifunctional flavokinase/flavin adenine dinucleotide synthetase from Streptomyces davawensis produces inactive flavin cofactors and is not involved in resistance to the antibiotic roseoflavin. J Bacteriol 2008; 190: 1546-53.
42. Demain AL. Riboflavin oversynthesis. Annu Rev Microbiol 1972; 26: 369-88.
43. Bandrin SV, Beburov M, Rabinovich PM, Stepanov AI. [Riboflavin auxotrophs of Escherichia coli]. Genetika 1979; 15: 2063-5.
44. Shinkai S, Kameoka K, Honda N, Ueda K, Manabe O, Lindsey J. Spectral and reactivity studies of roseoflavin analogs: correlation between reactivity and spectral parameters. Bioorganic chemistry 1986; 14: 119-33.
45. Nakanishi M, Yatome C, Ishida N, Kitade Y. Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase. J Biol Chem 2001; 276: 46394-9.
46. Ito K, Nakanishi M, Lee WC, et al. Three-dimensional structure of AzoR from Escherichia coli. An oxidereductase conserved in microorganisms. J Biol Chem 2006; 281: 20567-76.
47. Reddick JJ, Saha S, Lee J, Melnick JS, Perkins J, Begley TP. The mechanism of action of bacimethrin, a naturally occurring thiamin antimetabolite. Bioorg Med Chem Lett 2001; 11: 2245-8.
48. Fiehe K, Arenz A, Drewke C, Hemscheidt T, Williamson RT, Leistner E. Biosynthesis of 4'-O-methylpyridoxine (Ginkgotoxin) from primary precursors. J Nat Prod 2000; 63: 185-9.
49. Serganov A, Huang L, Patel DJ. Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. Nature 2009; 458: 233-7.
50. Jankowitsch F, Schwarz J, Rückert C, Gust B, Szczepanowski R, Blom J, Pelzer S, Kalinowski J, Mack M. The genome sequence of the bacterium Streptomyces davawensis JCM 4913 and heterologous production of the unique antibiotic roseoflavin. J Bacteriol 2012; Oct 5. [Epub ahead of print] PubMed PMID: 23043000.
51. Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, Inui K. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr 2010; 140: 1220-6.
52. Yonezawa A, Masuda S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol 2008; 295: C632-41.
53. Karthikeyan S, Zhou Q, Mseeh F, Grishin NV, Osterman AL, Zhang H. Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch. Structure 2003; 11: 265-73.
54. Brizio C, Galluccio M, Wait R, et al. Over-expression in Escherichia coli and characterization of two recombinant isoforms of human FAD synthetase. Biochem Biophys Res Commun 2006; 344: 1008-16.
55. Galluccio M, Brizio C, Torchetti EM, et al. Over-expression in Escherichia coli, purification and characterization of isoform 2 of human FAD synthetase. Protein Expr Purif 2007; 52: 175-81.
56. Torchetti EM, Brizio C, Colella M, et al. Mitochondrial localization of human FAD synthetase isoform 1. Mitochondrion 2010; 10: 263-73.
57. Pedrolli DB, Nakanishi S, Barile M, et al. The antibiotics roseoflavin and 8-demethyl-8-amino-riboflavin from Streptomyces davawensis are metabolized by human flavokinase and human FAD synthetase. Biochem Pharmacol 2011; 82: 1853-9.
58. Becker K, Christopherson RI, Cowden WB, Hunt NH, Schirmer RH. Flavin analogs with antimalarial activity as glutathione reductase inhibitors. Biochem Pharmacol 1990; 39: 59-65.
59. Rivlin RS. Riboflavin and cancer: a review. Cancer Res 1973; 33: 1977-86.
60. Aposhian HV, Lambooy JP. Retardation of growth of Walker rat carcinoma 256 by administration of diethyl riboflavin. Proc Soc Exp Biol Med 1951; 78: 197-9.
61. Kim YS, Aposhian MM, Lambooy JP. The influence of homologs of riboflavin on the growth of Walker rat carcinoma 256. Cancer Res 1966; 26: 1344-8.
62. Lambooy JP, Aposhian HV. The biological activity of diethyl riboflavin. J Nutr 1952; 47: 539-59.